MKTX · MarketAxess Holdings, Inc.

The thesis

MarketAxess Holdings' $167-per-share cash sale to Intercontinental Exchange (ICE) lost its main US antitrust risk on 21 October 2026, and the shares now trade on the 29 October shareholder vote and the remaining foreign approvals. The Department of Justice and the Federal Trade Commission granted early termination of the Hart–Scott–Rodino waiting period effective 21 October, per a MarketAxess Form 8-K. The earlier note's open question, a possible second request on 29 October, is closed.

The shares closed at $164.66 on 22 October 2026, below the $167 deal price. The narrative is saturated: the price is fixed by contract, every major analyst target sits at $167, and the 8-K states that stockholder approval and other regulatory approvals remain conditions to closing. Upside is capped at the deal price, so the case for beating the S&P 500 over three months stays weak even with the lower risk.

Bullish and bearish views on MarketAxess Holdings, Inc.

The bull case on MarketAxess Holdings, Inc. (MKTX), in brief: US antitrust condition is satisfied. The bear case: Other approvals remain open.

Bull case

• US antitrust condition is satisfied. The 8-K reports early termination of the waiting period effective 21 October 2026, eight days before the expiry that followed the 29 September refiling. The parties had withdrawn and refiled on 25 September and 29 to give the Department of Justice more time.
• Cash terms remain fixed. The 29 July 2026 merger agreement pays $167 per share in cash, with no exchange ratio. ICE's own share price does not change what MarketAxess holders receive.
• Analysts treat $167 as the value. Morgan Stanley raised its target to $167 on 9 October 2026, after UBS (31 July), Barclays (10 August) and Keefe, Bruyette & Woods (11 August) set the same figure.
• The board backs the deal. The 18 September 2026 definitive proxy says the board unanimously recommends adoption at the 29 October meeting.
• The business is profitable while it waits. MarketAxess reported second-quarter 2026 revenue of $218.4 million and net income of $68.3 million on 7 August 2026.

Bear case

• Other approvals remain open. The 18 September 2026 proxy lists required approvals in Canada, the Netherlands, the United Kingdom and Singapore, and the 21 October 8-K says other regulatory approvals are still outstanding. Press reports repeat ICE's expected closing in the first half of 2027.
• The vote has a high bar. Adoption needs a majority of outstanding shares, so abstentions and non-votes count against it, per the 18 September proxy.
• Upside is limited. The shares closed at $164.66 on 22 October, against a fixed $167 cash price. The 52-week high of $191.62 predates the 29 July announcement.
• Operating information is thin. MarketAxess suspended earnings calls and monthly volume releases on 30 July 2026, so the shares carry little fresh business data.

Price setup

The adjusted daily close on 22 October 2026 was $164.66, up from $164.58 on 9 October. The 14-day relative strength index was 64.8, down from 76.9 on 9 October. The three-month price change was 40.3%. The close is 14.1% below the 52-week high of $191.62.

The antitrust news on 22 October left the price almost unchanged from 9 October. The market appears to have priced the clearance already, and the remaining distance to $167 reflects the time to closing and the foreign approvals.

The research threshold is a daily close below $155, published 30 August 2026. A close that low would show the market pricing a real chance of failure or a much longer delay.

Crowding evidence is limited. The shares trade as a merger-arbitrage position, and the vote and the ICE earnings call fall on the same day, 29 October.

Catalysts, next 30 days

• After the vote: A Form 8-K with vote results should follow. Foreign approval filings carry no confirmed dates.

Elapsed catalysts

• 29 October 2026, 8:30 a.m. Eastern: ICE third-quarter earnings call. ICE may update the expected closing period and the status of non-US approvals. (passed 8d ago)
• 29 October 2026, 9:00 a.m. Eastern: MarketAxess special shareholder meeting. A majority of outstanding shares must adopt the merger agreement. (passed 8d ago)

What would change the view

The case breaks if the 29 October vote fails, if a regulator in Canada, the Netherlands, the United Kingdom or Singapore delays or denies approval, or if a filing terminates the 29 July merger agreement. Any of these would remove the $167 cash price as the anchor for the shares.

On price, a daily close below $155 would put the shares well under the deal price and show the market expects failure or a long delay. A vote approval and a sign-off from the named foreign regulators would leave the shares tied to the closing date, with upside still capped at $167.

What it trades with

The shares trade on deal-completion odds and the time to closing, not on operating results. Their moves link more closely to ICE's regulatory disclosures and credit-market conditions for acquisition financing than to bond-trading volumes or equity-market direction. ICE's own share price does not set the MarketAxess payout because the consideration is cash.